A comparative study of visual outcome in patients with optic neuritis treated with five or seven days of intravenous corticosteroid treatment

Imagem de Miniatura
Arquivos
art_SILVA_A_comparative_study_of_visual_outcome_in_patients_2023.PDF (526.45 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
Citação
MULTIPLE SCLEROSIS AND RELATED DISORDERS, v.75, article ID 104737, 5p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Optic neuritis (ON), a major cause of visual impairment in young adults, is generally associated with rapid visual recovery when treated with intravenous methylprednisolone treatment (IVMPT). However, the optimal duration of such treatment is unknown, ranging from three to seven days in clinical practice. We aimed to compare the visual recovery in patients treated with 5-day or 7-day duration IVMPT.Methods: We performed a retrospective cohort study of consecutive patients with ON in Sa similar to o Paulo, Brazil, from 2016 to 2021. We compared the proportion of participants with visual impairment in 5-day and 7-day treatment schedules at discharge, at 1 month and between 6 and 12 months after the diagnosis of ON. The findings were adjusted to age, severity of the visual impairment, co-intervention with plasma exchange, time from symptom onset to IVMPT and the etiology of the ON to mitigate indication bias.Results: We included 73 patients with ON treated with 5 or 7-day duration of 1 g/d intravenous methylprednisolone therapy. Visual impairment at 6-12 months in the 5-day or the 7-day treatment groups was similar (57% x 59%, p > 0.9, Odds Ratio 1.03 [95% CI 0.59-1.84]). The results were similar after adjusting for prognostic variables and when observed at different time points.Conclusion: Visual recovery is similar in patients treated with 5-day and 7-day duration treatments of 1 g/day intravenous methylprednisolone, suggesting a ceiling effect. Limiting the duration of the treatment can reduce hospital stay and costs, without interfering with clinical benefit.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/54711
Referências
  1. BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901
  2. Buttgereit F, 2002, ANN RHEUM DIS, V61, P718, DOI 10.1136/ard.61.8.718
  3. Campana I.G., 2021, NEUROIMMUNOL REP, V1, DOI [10.1016/j.nerep.2021.100045.VolumeISSN, DOI 10.1016/J.NEREP.2021.100045.VOLUMEISSN]
  4. Ducloyer JB, 2022, EUR J OPHTHALMOL, V32, P754, DOI 10.1177/11206721211028050
  5. Le Page E, 2016, LANCET, V387, P340
  6. Le Page E, 2015, LANCET, V386, P974, DOI 10.1016/S0140-6736(15)61137-0
  7. Petzold A, 2014, NAT REV NEUROL, V10, P447, DOI 10.1038/nrneurol.2014.108
  8. Saitakis G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23179769
  9. von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010

Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - FM/MOF
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/33
Carregar mais